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Abstract
Adult mesenchymal progenitor cells have enormous potential for use in regenerative medicine.
However, the true identity of the progenitors in vivo and their progeny has not been precisely
defined. We hypothesize that cells expressing a smooth muscle α-actin promoter (αSMA) directed
Cre transgene represent mesenchymal progenitors of adult bone tissue. By combining
complementary colors in combination with transgenes activating at mature stages of the lineage
we characterized the phenotype and confirmed the ability of isolated αSMA+ cells to progress
from a progenitor to fully mature state. In vivo lineage tracing experiments using a new bone
formation model confirmed the osteogenic phenotype of αSMA+ cells. In vitro analysis of the in
vivo labeled SMA9+ cells supported their differentiation potential into mesenchymal lineages.
Utilizing a fracture-healing model, αSMA+ cells served as a pool of fibrocartilage and skeletal
progenitors. Confirmation of the transition of αSMA+ progenitor cells to mature osteoblasts
during fracture healing was assessed by activation of bone specific Col2.3emd transgene. Our
findings provide a novel in vivo identification of defined population of mesenchymal progenitor
cells with active role in bone remodeling and regeneration.
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INTRODUCTION
A full understanding of the recruitment of multipotent progenitors into the skeletal lineage
and the factors influencing their differentiation is critical to the development of protocols to
modulate bone regeneration and to the design of novel targets for pharmacological
intervention. However, a major obstacle has been the unavailability of reproducible methods
to identify these progenitors and to track their fate. Initial studies have characterized some
phenotypic properties of these cells, but have not provided clear information on their origin.
A perivascular niche has been implicated as a source of mesenchymal progenitors 1, 2. The
human bone marrow derived stromal population expressing STRO-1 and CD146 exhibits the
ability to form bone in vitro and in a heterotopic bone formation assay in vivo. This
population of cells is localized in the proximity of endothelial cells and was positive for
αSMA expression 3. Sacchetti et al. defined a population of osteoprogenitors as CD146+
subendothelial cells in bone marrow suggesting that perivascular cells exhibit potential for
self-renewal and differentiation supportive of hematopoiesis 4. Crisan et al observed
perivascular cells in various organs with the ability to differentiate into multiple
mesenchymal lineages 5.
Recently, we described a population of cells expressing smooth muscle actin alpha (αSMA)
that have osteogenic potential 6. The αSMAGFP cells are located in perivascular niches,
periosteum and sutures, regions that contain osteoprogenitor cells. Moreover,αSMAGFP+
cells derived from primary BMSCs and ADSCs of transgenic mice exhibit osteogenic and
adipogenic potential 6. A high proportion of αSMAGFP+ cells express the stem cell
markers; stem cell antigen 1 (Sca1) and CD90 but lack expression of the CD117 (c-kit) or
CD11b 7–9.
A detailed characterization of progenitor cells requires methods to isolate the cells and trace
their transition into different phenotypes. The use of cell surface markers is limited by the
fact that progenitor cells may loose markers as they differentiate.
We have generated αSMACreERT2 transgenic mice, which provide the system in which the
fate of the progenitors could be traced. We propose to examine the ability of
αSMACreERT2 expressing cells as mesenchymal progenitors during bone formation and
repair and to determine whether these progenitor cells become committed to specific
lineages. The combinatorial approach of using Cre recombinase fused to a modified estrogen
receptor ligand binding domains (ERT2) permits the temporal induction by delivery of a
tamoxifen and tissue specificity by directing the Cre expression with a lineage specific
promoter 10. When crossed with Ai9 reporter mice, recombination can be detected by
expression of red fluorescence (TdTomato) 11. This system allows for the spatial and
temporal activation of Cre labeling and identifying the labeled population, and tracing the
lineage progenies of the labeled cells for prolonged period after the tamoxifen treatment has
been terminated. Here we utilized the visual markers for transgene expression and the Cre/
loxP recombination system for lineage tracing using a fragment of the αSMA promoter 6.
We have utilized murine models harboring real-time visual transgenes in combination with
cell surface markers and Cre/loxP technology as a powerful way of characterizing
mesenchymal progenitors.
These approaches have defined a mesenchymal progenitor cell in vivo that actively
participates in the physiological process of bone remodeling and during the regenerative
processes of fracture healing.
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MATERIALS AND METHODS
Generation of transgenic mice and animal studies
Detailed description of generation of αSMACreERT2 mice is outlined in the Suppl.
Methods. The generation and characterization of αSMAGFP, Col2.3cyan, Col2a1cyan and
Col2.3emd mice has been published 6, 12, 13. Mice transgenic for AP2cyan and αSMAcherry
have been recently developed 14. The αSMACreERT2/Ai9 dual transgenic mice mice (term
SMA9 will be used) were generated by breeding αSMACreERT2 male mice and Ai9 female
mice that were obtained from Jackson labs (stock # 007909). The Ai9 mice harbor a targeted
mutation of the Gt(ROSA)26Sor locus with a loxP-flanked STOP cassette preventing
transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato). For in
vivo lineage tracing studies 4–5 weeks old mice were treated with tamoxifen at the dose of
75 μg/g of weight. Mice were treated twice in the interval of 24 hours and sacrificed 2 days
or 17 days later. The SMA9 untreated mice and αSMACreERT2 negative/Ai9 treated mice
were evaluated as controls.
In vitro studies
Primary BMSC were prepared as previously described 15. Following cell separation using
fluorescent activated cell sorting (FACS), cells were plated at the density of 10,000 cells/
cm2 in 24 well plates. Cells were induced to osteogenesis using DMEM/10%FCS medium
supplemented with 50μg/ml ascorbic and 8mM β-glycerol phosphate for two weeks, while
adipogenesis was induced media supplemented with 1μM Insulin and 0.5μM rosiglitasone
for 7 days. To evaluate chondrogenesis sorted SMA9+ and SMA9− population were seeded
as a 20μl spot containing 5×104 cells. After 2hr, αMEM/10%FCS was added and cells were
for 7 days, placed under chondrogenic induction (serum free media supplemented with
50μg/ml ascorbic acid, 10ng/ml TGFβ3, 100nM dexamethasone, 40μg/ml L-proline,
sodium pyruvate, ITS+ 1 and cultured in 5% oxygen). Methods evaluating osteogenesis,
adipogenesis and chondrogenesis in vitro are presented within Suppl. Methods section.
Histology
Bone samples for histology were fixed for 3–5 days in 10% formalin (Sigma) and
decalcified in 15%EDTA for 4–7 days depending on the age of animal, placed in sucrose
overnight and embedded in cryomedium (Thermo scientific). Soft tissues were fixed
overnight and after 24 hours in sucrose they were embedded and sectioned. Sections of 5μm
were obtained using a Leica cryostat and tape transfer system (Japanese tape). Images were
obtained by appropriate filter cubes optimized for GFP variants (Chroma) using a Zeiss
Observer.Z1 microscope. Images were obtained in grey scale, pseudocolored and composite
images assembled. To obtain a full size image of bone, images were scanned at high power
and then stitched into a composite. Following fluorescent imaging sections were stained
with hematoxyllin and imaged. Cells embedded within the bone matrix were counted within
the trabecular area using sections counterstained with DAPI to visualize the population of
osteocytes.
Flow cytometry
FACS analysis and cell sorting of αSMAcherry+, and αSMACreERT2/Ai9 cells were
performed using a BD FACSAria I (BD Biosciences. San Jose, CA, USA) equipped with
five lasers and 18 fluorescence detectors. Flushed bone marrow cells, and enzymatically
digested (collagenase 0.2%, hyalouronidase 0.2% in 0.25 trypsin) periosteal layer cells were
used. Erythrocytes were lysed by hypotonic shock. Sorting gates were defined using cells
from non-transgenic and transgenic mice bearing individual transgenes. Single cell
suspensions were prepared in staining medium (2% FCS/HBSS/HEPES). For phenotype
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characterization we used commercially available antibodies (Ab) as described in detail in
Supp. Material.
RESULTS
αSMA+ cells exhibit characteristics of mesenchymal progenitor cells
To evaluate the localization of cells expressing αSMA we analyzed mice expressing cherry
FP under the control of αSMA promoter. In bone marrow and periosteum we observed
αSMAcherry+ cells in association with microvasculature. In addition to perivascular
location, we observed αSMAcherry+ fibroblastic shaped cells in periosteum (figure 1a–d,
see suppl. figure 1a for whole bone section). FACS analyses of freshly isolated cells
indicated that the αSMA transgene is active in 0.02–0.03% of cells in bone marrow and in
around 1% of scraped cells from periosteum (figure 1e–h). The identified population in bone
marrow can be expanded in vitro by day 7 (figure 1i). To assess the ability to differentiate
into osteogenic lineage αSMAcherry+ and αSMAcherry− population were sorted from a
dual transgenic mouse harboring the osteoblast specific reporter, Col2.3cyan (figure 1j).
These cells were then replated and grown under lineage inductive conditions. We confirmed
that αSMAcherry+ cells differentiated into mature osteoblasts and expressed Col2.3cyan on
day 7 (figure 1l) and day 14 (figure 1n). In contrast, αSMAcherry− cells did not generate
colonies or express osteogenic marker (figure 1k, m). The profile of cells derived from
αSMAcherry+ population was confirmed by alkaline phosphatase expression, mineralization
and the expression of bonesialoprotein and osteocalcin (figure 1o–p). Similar experiments
driving sorted cells into adipogenesis and chondrogenesis, showed that the αSMAcherry+
population has the ability to differentiate into mature adipocytes and chondrocytes.
Adipogenesis was detected by staining for oil-red-o and expression of AP2cyan and mRNA
for adipsin and adiponectin (suppl. figure 1b), while chondrogenic differentiation was
analyzed by alcian blue staining and aggrecan mRNA expression (data not shown).
Lineage tracing identifies progenitor population during normal skeletal remodeling
In order to determine whether αSMA promoter can identify cells with progenitor activity in
vivo, we generated αSMACreERT2 transgenic mice and we characterized its expression by
crossing it with the Ai9 reporter transgenic line to generate αSMACreERT2/Ai9 (SMA9)
mice (figure 2a). In these mice the expression of the Cre molecule is activated under the
control of the αSMA promoter upon treatment with tamoxifen. This allows the tracking of
developmental progression of αSMA expressing cells by activating the expression of the
tdTomato visual reporter through Cre-mediated recombination. Mice were treated with
tamoxifen and analyzed at days 2 and 17 after treatment (figure 2b–d). Two days after
treatment SMA9+ cells defined a small population of cells present in primary spongiosa
(figure 2c) or within the periosteum (suppl. figure 2a). No cells expressing SMA9 reporter
were detected within the bone matrix (figure 2c). Interestingly, 17 days after the tamoxifen
activation we found numerous osteoblast and osteocytes labeled by the transgene. Image
analysis revealed that 23.4±3.2% of bone matrix embedded cells were SMA9+ at this time
point. These observations confirm the ability of the αSMA directed Cre to target
osteoprogenitor cells in vivo (figure 2d). We have confirmed that the αSMACreERT2
activity was ligand dependent in adult bone and other tissues. In the absence of tamoxifen
we did not detect leaky expression of tdTomato in bone tissue (suppl. figure 2a) However, a
significant leak of the Cre expression was observed in tissues with a strong endogenous
activity of αSMA gene like bladder, and aorta (suppl. figure 2b).
To further evaluate the distribution of labeled cells generated after αSMACre activation, we
analyzed primary cultures at days 3 and 7 by flow cytometry. We did not detect expression
of tdTomato in cells derived from αSMACrenegative/Ai9/Tx treated mice (figure 2f, i) at
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days 3 or 7, or in cells derived from SMA9 untreated mice on day 3 in culture (figure 2g).
However, an appreciable activation of Cre-directed recombination was observed in SMA9
treated mice by day 3 (1–2%) and by day 7 (23–27%) (figure 2h, k). A small proportion of
cells showed a spontaneous Cre activation in primary cultures derived from SMA9 non-
treated mice (figure 2j) by day 7. The spontaneous activation of SMACreERT2 transgene in
vitro is due the increase of SMA promoter activity and the presence of number of serum
response elements in the proximal sequence of SMA promoter 16.
In addition, primary cultures derived from untreated SMA9 mice, subsequently treated in
vitro by 4-OH tamoxifen, showed expression of tdTomato in a similar proportion of cells
(suppl. figure 2c). This confirms our in vivo observation that we are selectively targeting a
progenitor population that exhibits ability to differentiate into mature osteoblasts in vivo and
in vitro.
Differentiation potential of SMA9 labeled progenitor population
To test the progenitor ability of the in vivo labeled SMA9 cells we established primary
cultures from SMA9 mice that were treated with tamoxifen for 2 days (figure 2b). Following
one day in culture, individual SMA9+ cells were evident, and over time they expanded in
number forming colonies during the first 7 days of culture (figure 2e). After induction of
osteogenic differentiation SMA9+ cells formed multilayered nodules with the ability to
mineralize. To substantiate these results, we have utilized primary BMSC cultures derived
from SMA9/AP2Cyan and SMA9/Col2.3emd mice treated with tamoxifen. Two days after
treatment, cultures were established and after reaching confluence were induced to
adipogenesis and osteogenesis. We have observed numerous SMA+ cells differentiating into
adipocytes or osteoblasts as detected by the expression of AP2cyan (figure 3b–c), or
Col2.3emd respectively (figure 3e–f). To evaluate chondrogenic differentiation SMA9 mice
were utilized, and cells we sorted into SMA9+ and SMA9− populations on day 7 of culture.
Following differentiation we observed the formation of alcian blue positive nodules in the
cultures derived from SMA9+ cells (figure 3i). Cultures of unsorted or SMA9− cells did not
form alcian blue positive nodules (figure 3g–h) even after longer period in culture. The
SMA9+ population shows also enhanced mRNA expression of chondrogenic markers
Col2a1 and aggrecan (data not shown).
Our data clearly shows that the SMA9 transgenic constructs provided a bona-fide
identification of mesenchymal progenitor cells and should allow further characterization of
this population of cells using markers currently proposed as signature molecules for stem
cells.
Multiple mesenchymal stem cell markers are present on SMA9 labeled cells
In addition to the histological assessment, we followed the percentage of SMA9+ labeled
cells in vivo at days 2 and 17 after tamoxifen treatment by flow cytometry. We found an
increase in the percentage of cells expressing tdTomato reporter in the bone marrow up to
0.3% at day 17, compared to the 0.02% observed for the expression of αSMAcherry in basal
conditions (figure 4a). In contrast, the percentage of SMA9+ cells isolated from the
periosteal layer was approximately 1% and was maintained along a time-course evaluation
(figure 4b, and suppl figure 3a). We used multicolor FACS analysis to test if the reporter
signal correlated to markers of the hematopoietic lineage. To evaluate hematopoietic
markers we used a combination of antibodies for CD45, Ter119 and CD11b. Interestingly,
most of the SMA9+ cells present in the bone marrow cells expressed markers characteristic
of hematopoietic lineage, whereas the majority of the SMA9+ periosteal cells were (CD45/
Ter119/CD11b)− (figures 4a–b). Among the (CD45/Ter119/CD11b)− SMA9+ bone marrow
population, approximately one third of the cells were CD45+Ter119−CD11b− (not shown).
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We also analyzed gated SMA9+ cells for the co-expression of cell surface markers
associated with mesenchymal progenitor cells and found that SMA9+ population maintained
a stable expression pattern when analyzed at day 2 and 17 after transgene induction (figures
4c–d, suppl figure 3b). Bone marrow cells that are tdTomato+ and (CD45/Ter119/CD11b)−
were mostly negative for the included mesenchymal lineage markers, except for CD31 that
was weakly expressed on approximately 5% cells on day 17(figure 4c).
Percentages of hematopoietic marker positive SMA9+ bone marrow cells expressing
mesenchymal markers vary between 10–30%, with CD31 being the most prominently
expressed (figure 4c). This percentage of CD31+ cells was much lower (<0.1%) in
αSMAcherry labeled cells (data not shown), indicating induction of CD31 expression after
tamoxifen activation of Cre mediated recombination.
The periosteal SMA9+ cells had a different phenotype, mostly lacking expression of
hematopoietic markers but strongly expressing Sca1 and CD90 on approximately 20% of the
population and weakly expressing CD51 on approximately a third of the population at day 2
after transgene induction (figure 4d and suppl. figure 3b).
The in vitro system allows for the expansion of the progenitor population, but comes with a
number of variables including serum composition and selective expansion of the adherent
population of cells. Therefore, we evaluated the expression of cell surface markers that are
used to characterize mesenchymal progenitor cells in vitro. Following our in vivo indication
that majority of SMA9+ bone marrow cells are positive for the hematopoietic lineage
markers we have evaluated the expression of SMA9+ cells for the presence of Sca1, CD51,
CD140b, CD31 and CD146 in the context of the and CD45/Ter119 expression. During the
first 3 days in culture SMA9+ cells lose the expression of CD45/Ter119, which is present in
about 2% of cells on day 3 and 6% on day 7 (suppl. fig. 4). The expression of Sca1 and
CD51 was observed by 30–40% of cells on day 3 and increased up to 50–60% of cells on
day 7, while CD140b was expressed at much lower levels (suppl. fig. 4). We did not observe
the expression of CD31 or CD146 in primary stromal cell cultures at either time point (not
shown).
Origin of mesenhymal lineages during fracture repair
To determine whether SMA9 expressing cells participate in the regenerative processes
including generation of chondrocytes and osteoblasts we utilized a tibia fracture model. The
experimental design included treatment with tamoxifen, on the day before and on the day of
fracture. The aim was to label the population of αSMA expressing cells and then trace their
progeny during the fracture healing process.
During the first week following injury expansion of SMA9+ cells within bone marrow and
periosteum was observed (figure 5a). Interestingly, we detected the presence of SMA9+
expressing cells in newly formed chondrogenic areas of the fracture callus, and areas of the
new bone formation (figure 5b). We correlated the presence of these osteoblasts with the
dynamic formation of new bone through injection of calcein dye one day before sacrificing
the mice. The osteoblasts derived from SMA9+ progenitor cells showed intense deposition
of new bone, indicated by the correlation between calcein label (green) and tdTomato (red)
positive cells (figure 5b). These results clearly indicated that the labeled populations present
within the periosteum and bone marrow actively participate in all the aspects of
fibrochondral ossification.
To track the population of SMA9+ cells into mature osteoblast we bred a bone specific
transgene into the SMA9 mice. The expression of SMA9+ cells (red-tdTomato) co-localized
to Col2.3emd expressing mature osteoblasts (green, SMA9/2.3GFP) (figure 5d–g). This
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finding is direct evidence for terminal differentiation of SMA9+ cells into mature osteoblasts
in vivo. A representative image of a control fractured bone from SMA9 mouse not injected
with tamoxifen is shown in figure 5c. No major leak of spontaneous Cre expression was
detected following fracture of SMA9 untreated mice.
The majority of the cartilaginous callus cells were SMA9+ indicating differentiation into
chondrocytes (figure 5b and 5f–g arrowheads). In addition to the morphological
characterization of chondrocyte we have introduced a chondrocyte lineage directed reporter
(Cyan) using a Col2a1 transgene. One week following bone fracture in SMA9/Col2a1 mice
we have observed a population of dual SMA9/Col2a1Cyan expressing cells indicating that
the SMA9+ population labeled prior to fracture healing can gave rise to Col2a1 expressing
cells (suppl. figure 5).
To define the contribution of the SMA9 mesenchymal progenitor cells to newly formed
bone following completion of the fracture healing process we assessed the 6-week post-
fracture time point. Mice transgenic for SMA9/Col2.3emd were fractured and cell-lineage
traced following callus remodeling (figure 6). The contribution of the SMA9+ cell was
detected by persistence of the dual SMA9+/Col2.3emd labeled cells (osteoblasts and
osteocytes) within the new bone 6 weeks into the repair process (figure 6a–d, arrows
indicate numerous dual SMA9/Col2.3emd expressing osteoblasts and osteocytes).
DISCUSSION
Skeletal stem cell, as a term, has been proposed for the population of mesechymal
progenitor cells residing within bone marrow compartment 17, 18. The most accepted
markers to define human MSCs are STRO-1, recognizing a milieu of cell surface
glycoproteins, and MCAM/CD146, a marker that has been associated with subendothelial
perivascular cells 5, 19. Recently, the expression of nestin driven reporters has been
associated with a population of bone marrow cells that can differentiate into mesenchymal
lineages 20. Although useful to isolate cells from bone marrow and primary cell cultures,
these markers do not allow for lineage tracing of the progeny of the mesenchymal stem cell
since they are only transiently expressed at certain stages of differentiation.
The origin of the mature osteoblast remains elusive. We hypothesize that the αSMA
transgene expression could be a marker for a cell that can give rise not only to osteoblasts
but also to other mesenchymal lineage cells. We have addressed this by using an
αSMACreERT2 transgene aiming to confirm the progenitor potential of αSMA expressing
perivascular cell in vivo. We were able to trace the progeny of the perivascular cell into the
mature osteoblasts and osteocytes, the final stage of skeletal lineage differentiation. These
data indicate that during the process of bone formation and remodeling the αSMA transgene
identifies skeletal stem cells.
These observations prompted us to define the surface markers in the cells identified by
αSMAcherry as well as SMA9 expression. A high proportion of αSMAcherry+ and SMA9+
cells, expressed markers associated with hematopoietic cells including CD45. The
exclusiveness of CD45 as pan-hematopoietic marker has been recently challenged,
indicating that mesenchymal progenitor cells can express markers currently used to define
hematopoietic lineage 21,22. Skeletal stem cell interactions with endothelial cells are critical
for early invasion of vasculature during embryonic development and for the translocation of
skeletal stem cells into the newly formed bone marrow cavity 23. However, recent literature
has proposed alternative definitions for the identity of the mesechymal progenitor cells
regarding their expression of endothelial cell markers. Medici et al. described cells with
endothelial phenotype exhibiting the ability to differentiate into mesenchymal cell
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lineages 24. Other report, using a co-culture model of human embryonic stem cells with
mouse OP9 stromal cells, defined a common precursor for endothelial and mesenchymal cell
lineages, termed mesenchymoangioblast 25. These studies cannot be strictly compared as
they are derived from different experimental models. However, they provide evidence for a
close relationship between mesenchymal and endothelial lineage cells. In our study we have
observed the expression of αSMAcherry in proximity to endothelial cells, while very few or
none αSMAcherry+ co-expressed CD31 marker. Nevertheless, when the progeny of the
SMA9 cells was traced in vivo we observed a weak co-expression of CD31 in
approximately 5% of the (CD45/Ter119/CD11b)−, SMA9+ cells. The proportion of CD31+/
SMA9+ cells represents about 30% of the cells positive for markers of hematopoietic
lineage. These findings suggest the possibility that SMA9 labeled progenitor cells, located in
the perivascular region, have the ability to mature into cells with an endothelial phenotype.
In addition, within SMA9+ bone marrow population that are positive for hematopoietic
markers we observed approximately 20% of CD146+/SMA9+ cells, while there were very
few or none CD146 expressing cells among periosteal layer or in vitro expanded SMA9+
cells. Future studies have to be aimed to define these populations using a combination of
approaches and multiple markers for both mesenchymal and endothelial lineages.
To test functionally the proposed hypothesis, the osteogenic potential of SMA9 labeled cells
was tested in a bone injury model. Our data indicate that the majority of the callus cells,
including chondrocytes and osteoblasts, are derived from SMA9 expressing cells.
Interestingly, the expansion of the SMA9 cells occurred both in periosteum and within bone
marrow, and resulted into SMA9+ cells with mature bone cell phenotypes contributing to the
fracture healing process. Our work provides direct in vitro and in vivo evidence that the use
of SMA9 labeled cells should allow the selective identification and isolation of progenitor
cells that participate actively in the fracture healing process. In combination with visual
markers of mature lineages, we could identify pathways important for lineage determination
that could provide therapeutic targets for the enhancement of the regenerative processes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. αSMAcherry expressing cells display osteoprogenitor potential
(a–d) The expression of αSMAcherry is localized to the perivascular area of capillaries
within periosteum and muscle (a–b, see arrows) and bone marrow (c–d, arrowheads).
(e–h) FACS analysis for αSMAcherry expression in samples derived from enzymatically
digested periosteum (e–f) or whole bone marrow from transgenic (g–h) or non-transgenic
mice (e, g). Proportion of αSMAcherry expressing cells is indicated in the right lower
corner of the plots (four αSMAcherry mice were analyzed individually and the
respresentative values are shown).
(i–j) Primary BMSC derived from αSMAcherry/Col2.3cyan mice were grown for 7 days
and imaged under transmitted (left), red (middle) and blue (right) epifluorescence.
αSMAcherry expression was present in fibroblastic shaped cells while no expression of
Col2.3cyan was detected (i). αSMAcherry-expressing cells (j, left panel, 23% of cells) were
collected by FACS sorting; reanalysis of the sorted population purity is shown for
αSMAcherry− and αSMAcherry+ cells (j, middle and left panels).
(k–l) Following sorting, cells were replated and induced to osteogenesis and FACS analyzed
on day 7. αSMAcherry− cells did not activate Col2.3cyan (k) while α-SMAcherry+ showed
differentiation into Col2.3cyan+ cells (l). Col2.3cyan was detected at day 14 in population of
differentiated α-SMAcherry+ cells (n), with no expression in α-SMAcherry− population
(m).
(o–p) Alkaline phosphatase expression and mineralization (arrows) was detected
inαSMAcherry+ cells in contrast to αSMAcherry− cells (o). Real-time PCR shows increased
expression of BSP and OC after osteogenic induction of α-SMAcherry+ cells (p).
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Figure 2. Cell lineage tracing experiments following in vivo transgene activation
(a) TheαSMACreERT2 transgenic construct harboring sequence of αSMA regulatory
elements. These mice were crossed with a Cre recombinase reporter strain Ai9. In dual
expressing SMA9 mice tamoxifen-induced Cre recombinase activates expression of
tdTomato.
(b) Diagram of experimental approach for the cell lineage tracing experiments. Mice were
sacrificed on day 2 and 17 following tamoxifen treatment and evaluated by histological
analysis. Primary BMSC were established from mice treated with tamoxifen and sacrificed
on day 2 after treatment.
(c–d) Histological analysis of SMA9 recombination identifies SMA9+ cells within the
trabecular area (TR) but not inside the bone matrix (arrowheads). No expression is observed
in the growth plate (GP) chondrocytes. Seventeen days after the initial evaluation (day 17)
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we could track the SMA9+ cells to osteoblasts lining trabecular bone (d, arrowheads) and
ostecytes embedded within bone (arrows). Shown are representative images of 6–7 mice per
group analyzed at each time point.
(e) Epifluorescent imaging of primary BMSC derived from SMA9 mice treated with
tamoxifen. Once labeled in vivo, SMA9+ cells expanded during the first week in culture
formed nodules and underwent mineralization (see arrow).
(f–k) FACS analysis of primary BMSC (days 3 (f–h) and 7 (j–k)) derived from SMA9+
labeled cells following tamoxifen injection in vivo was performed
onαSMACreERT2negative/Ai9 mice treated with tamoxifen (f, i), and SMA9 mice without
treatment (g, j) served as a controls. In vivo treatment labeled SMA9+ cells account for
about 1% of cells on day 3 and close to 25% on day 7 of the culture (h, k).
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Figure 3. Multilineage potential of SMA9 progenitor cells
(a–f) Primary BMSC were established from SMA9/Col2.3emd and SMA9/AP2cyan mice
treated with tamoxifen for 2 days. Cells were then grown to confluence and induced to
osteogenic or adipogenic differentiation respectively. Osteogenic differentiation was
confirmed by dual expression of red-labeled SMA9 (b), and green-labeled Col2.3emd
osteoblast lineage cells (c), (phase is shown in a). Adipogenic differentiation was confirmed
by dual expression of red-labeled SMA9 (e), and blue labeled AP2cyan adipocytes (f),
(phase is shown in d).
(g–i) To evaluate chondrogenesis cells derived from SMA9 mice cells were cultured for 7
days, and then sorted into SMA9+ and SMA9− and placed under chondrogenic conditions
for 9 days. Formation of chondrogenic nodules was detected using alcian blue staining in
sorted SMA9+ cells (i), in contrast to SMA− (h) and unsorted BMSC (g).
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Figure 4. Distinct phenotype of αSMACre labeled cells from the bone marrow compartment and
periosteum
(a–b) Left-side graphs present FACS analysis of the percentage of αSMAcherry and SMA9
labeled cells (SMA9+) (2 and 17 days following tamoxifen injection) within the bone
marrow (a) and among periosteal cells (b). Right-side graphs present relative proportion of
(CD45/Ter119/Cd11b)+ vs. (CD45/Ter119/Cd11b)− populations among αSMAcherry and
SMA9+ cells. Each group included 2–3 independent samples pooled from the respective
tissue of 2–3 mice. To determine the percentage of SMA9+ cells at least 2.5×106 cells for
bone marrow and 0.25×106 for periosteal cells were analyzed. Gates were set in accord to
the control populations from tamoxifen injected αSMACrenegative/Ai9 mice. Mice without
tamoxifen treatment, carrying the transgene SMA9 served for the Cre-leakage control and
contained a percentage of tdTomato+ cells comparable to the control mice (not shown).
(c–d). Phenotyping of SMA9+ cells 2 and 17 days following transgene activation. Graphs
represent the percentage of the population expressing respective mesenchymal cell markers
within (CD45/Ter119/Cd11b)+ vs. (CD45/Ter119/Cd11b)− compartments of the SMA9+
cells. FACS analysis was performed by gating SMA9+ cells and plotting them using markers
for hematopoietic lineage (CD45/Ter119/CD11b) vs respective proposed mesenchymal
lineage marker (Sca1, CD90, CD31, CD51 Cd140b, CD146 or CD106) within the bone
marrow (c) and periosteal cell populations (d). Values represent mean±SD of the percentage
of respective population from 2–3 independent samples pooled from 2–3 mice.
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Figure 5. Mesenchymal progenitor cell lineage tracing during fracture healing
(a–b) Osteogenesis during fracture healing is examined at one and two weeks following
fracture. The expression of SMA9 is detected in the periosteal layer of cells (a, arrowheads
point to the expanded SMA9+ cells within periosteum) located in the proximity to the
fracture site (indicated by perforated lines; CB-cortical bone, BM-bone marrow). One week
after fracture SMA9+ cells comprise most of the periosteal layer around fracture site. Bone
marrow is also filled with SMA9+ cells. Two weeks after the fracture new cartilaginous
callus formation is observed (b, arrowheads), while new bone formation is detected by
deposition of calcein (green). Osteogenic lineage cells labeled by the SMA9 reporter (red,
tdTomato+) persist in proximity to the large and intermingled calcein labeled areas within
the callus.
(c) Two week post fracture callus of a SMA9 control mouse (tamoxifen non treated)
showing extensive calcein labeling but minimal reporter leakage.
(d–e) The same experimental design was completed in a SMA9/Col2.3emd model. The
expression of SMA9+ cells (d, red,) co-localizes with the expression of osteoblast specific
marker Col2.3emd (e, green), as indicated by the presence of yellow color (overlay image,
f). To provide better orientation within the area of callus same sections were stained by
hematoxylin (g).
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Figure 6. SMA9+ cells contribute to new bone formation following fracture healing
(a–c) Osteogenesis following fracture healing and callus remodeling is examined at 6 weeks
following fractures. The expression of SMA9 (a), Col2.3emd (b) and the overlayed image
was evaluated for the presence of the dual expressing mature osteoblast lineage cells (c).
Hematoxylin staining of the same section has been completed following epifluorescence
imaging (d). The expression of SMA9 is detected in the periosteal layer of cells (a, c, see
arrowheads point to the expanded SMA9+ cells within periosteum), within the osteoblast
layer (c, indicated by arrows), among osteocytes and within the muscle. High magnification
(20x) clearly identifies the presence of numerous cells that express both SMA9 and
Col2.3emd markers (c, see yellow cells on the bone surface and within the bone matrix).
BM- bone marrow, and CB-cortical bone. For this experiment unilateral fractures were
performed in 3 mice.
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